Abstract:Background The increasing incidence of inflammatory bowel disease (IBD) has imposed heavy financial burdens for Chinese patients; however, data about their financial status and access to health care are still lacking. This information is important for informing patients with IBD about disease treatment budgets and health care strategies. Objective The aim of this study was to evaluate the economic status and medical care access of patients with IBD through the China Crohn’s & Colitis Foundation web-based platform in China. Methods Our study was performed in 14 IBD centers in mainland China between 2018 and 2019 through WeChat. Participants were asked to complete a 64-item web-based questionnaire. Data were collected by the Wenjuanxing survey program. We mainly focused on income and insurance status, medical costs, and access to health care providers. Respondents were stratified by income and the associations of income with medical costs and emergency visit times were analyzed. Results In this study, 3000 patients with IBD, that is, 1922 patients with Crohn disease, 973 patients with ulcerative colitis, and 105 patients with undetermined colitis were included. During the last 12 months, the mean (SD) direct and indirect costs for per patient with IBD were approximately US $11,668.68 ($7944.44) and US $74.90 ($253.60) in China. The average reimbursement ratios for most outpatient and inpatient costs were less than 50%. However, the income of 85.5% (2565/3000) of the patients was less than ¥10,000 (US $1445) per month. Approximately 96.5% (2894/3000) of the patients were covered by health insurance, but only 24.7% (741/3000) of the patients had private commercial insurance, which has higher imbursement ratios. Nearly 98.0% (2954/3000) of the patients worried about their financial situation. Thus, 79.7% (2392/3000) of the patients with IBD tried to save money for health care and even delayed their medical treatments. About half of the respondents (1282/3000, 42.7%) had no primary care provider, and 52.2% (1567/3000) of the patients had to visit the emergency room 1-4 times per year for the treatment of their IBD. Multivariate analysis revealed that lower income (P=.001) and higher transportation (P=.004) and accommodation costs (P=.001) were significantly associated with the increased number of emergency visits of the patients. Conclusions Chinese patients with IBD have enormous financial burdens and difficulties in accessing health care, which have increased their financial anxiety and inevitably influenced their disease outcomes. Early purchase of private insurance, thereby increasing the reimbursement ratio for medical expenses, and developing the use of telemedicine would be effective strategies for saving on health care costs.

PGI6 DISEASE BURDEN OF MODERATE TO SEVERE CROHN'S DISEASE UNDER CURRENT TREATMENT PATTERN IN CHINA

Economic Burden and Health Care Access for Patients with Inflammatory Bowel Diseases in China: Web-Based Survey Study

Treatment Decision-making in Chinese Inflammatory Bowel Disease Patients

Impacts of Disease Burden on Quality of Working Life in Chinese Patients with Inflammatory Bowel Disease: A Web-based Survey Study (Preprint)

PCN49 Disease Burden of Classical Hodgkin Lymphoma UNDER Current Treatment Pattern in China

PCN50 Disease Burden of Chronic Myeloid Leukemia UNDER Current Treatment Pattern in China

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

PCN46 Disease Burden of Chronic Lymphocytic Leukemia/SMALL Lymphocytic Lymphomaunder Current Treatment Pattern in China

PCN15 Disease Burden of Myelodysplastic Syndrome UNDER the Current Treatment Pattern in China

PCN21 Disease Burden of Multiple Myeloma UNDER the Current Treatment Pattern in China

PCN43 Disease Burden of NON-SMALL CELL Cancer UNDER Current Treatment Pattern in China

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

PCN51 Disease Burden of Mantle CELL Lymphoma UNDER Current Treatment Pattern in China

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

PCN47 Disease Burden of Gastric Cancer UNDER the Current Treatment Pattern in China

PCN44 Disease Burden of Follicular Lymphoma UNDER the Current Treatment Pattern in China

PCN52 Disease Burden of Prostate Cancer UNDER Current Treatment Pattern in China

PIN24 Disease Burden of Progressive Chronic Hepatitis C in China

PCN14 Disease Burden of Waldenstrom's Macroglobulinemia UNDER the Current Treatment Pattern in China

A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China

Disease Burden of Inflammatory Bowel Disease in China from 1990 to 2019 and Its Predictions